Can a little known drug in AstraZeneca's pipeline make a comeback as a PARP add-on? Yale scientists explain how

AstraZeneca’s cediranib may not have made the cut as a single agent to treat ovarian cancer, but Yale researchers think it could serve as a powerful add-on to amplify the effects of PARP inhibitors.